View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Deals Analysis
July 16, 2019

Pharma industry M&A deals in Q2 2019 total $114.8bn globally

Total pharma industry M&A deals in Q2 2019 worth $114.8bn were announced globally, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

The value marked a decrease of 10.7% over the previous quarter and a rise of 67.4% when compared with the last four-quarter average, which stood at $69.04bn.

Comparing deals value in different regions of the globe, Europe held the top position, with total announced deals in the period worth $87.84bn. At the country level, Ireland topped the list in terms of deal value at $85.88bn.

In terms of volumes, North America emerged as the top region for pharma industry M&A deals globally, followed by Europe and then Asia-Pacific.

The top country in terms of M&A deals activity in Q2 2019 was the US with 52 deals, followed by the UK with nine and Sweden with six.

In 2019, as of the end of Q2 2019, pharma M&A deals worth $251.63bn were announced globally, marking an increase of 52.3% year on year.

Pharma industry M&A deals in Q2 2019: Top deals

The top five pharma industry M&A deals accounted for 92.5% of the overall value during Q2 2019.

The combined value of the top five pharma industry M&A deals stood at $106.21bn, against the overall value of $114.8bn recorded for the quarter. The top announced pharma industry M&A deal tracked by GlobalData in Q2 2019 was AbbVie’s $85.74bn acquisition of Allergan.

In second place was the $11.4bn acquisition of Array BioPharma by Pfizer and in third place was Novartis’ $5.3bn asset transaction with Takeda Pharmaceutical.

The $2.2bn acquisition of Peloton Therapeutics by Merck &Inc and Novartis’ acquisition of IFM Tre for $1.58bn held fourth and fifth positions, respectively.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

 

Related Companies

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU